- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Chimerix Inc.
Headquarters: Durham, NC, United States of America
Website: https://www.chimerix.com/
Year Founded: 2002
Status: Public
Industry Sector: HealthTechnology
CEO: Michael T. Andriole, MBA
Number Of Employees: 72
Enterprise Value: $-95,409,625
PE Ratio: -9.05
Exchange/Ticker 1: NASDAQ:CMRX
Exchange/Ticker 2: N/A
Latest Market Cap: $787,177,600
BioCentury | Mar 10, 2025
Deals
Sun takes shine to Checkpoint in $355M buyout: Deals Report
Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum
BioCentury | Mar 5, 2025
Deals
Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz
Building in oncology, Jazz obtains targeted glioma therapy under FDA review
BioCentury | Oct 29, 2024
Management Tracks
Ernest Mario, Pappas partner who steered Alza into J&J deal, passes away
“His counsel and legacy will always remain with us,” says Pappas team
BioCentury | Mar 7, 2024
Politics, Policy & Law
Lessons from a compassionate use firestorm
Arthur Caplan assesses the impacts of the 2014 campaign to get Josh Hardy compassionate use
BioCentury | Mar 6, 2024
Discovery & Translation
Distillery spotlight: new Type II diabetes mechanisms from academia
New targets to drive insulin secretion, islet cell numbers and receptor localization from BioCentury’s survey of the 2023 translational literature
BioCentury | Dec 6, 2023
Management Tracks
Catalyst hires Michael Kalb as CFO
Plus: Raab to become Amicus chair when Crowley heads to BIO and updates from AC Immune, Gossamer Bio, Chimerix, Versameb, Alzheon, Kling and Avalere
BioCentury | Nov 17, 2023
Management Tracks
FDA chief of staff shifting to CBER
Plus: Biden to appoint Kimryn Rathmell as NCI’s director and updates from 1910 and Chimerix
BioCentury | Jun 28, 2023
Management Tracks
Zhong, Malhotra to succeed Nicaise at Ovid
Plus: Chimerix promotes Andriole to CEO and updates from Appia, Verily and the Lung Cancer Research Foundation
BioCentury | Jun 14, 2022
Product Development
Poxvirus agents, by the mechanisms
The mechanisms of products approved for monkeypox and other orthopoxviruses offer the potential for combinations
BioCentury | Jun 3, 2022
Editor's Commentary
Fix three wrongs to make advisory committees right
A prescription for getting FDA the external advice it needs and the public deserves
Items per page:
1 - 10 of 173